Login
$SRRK
$44.54 +$1.34 (3.09%) Live

Company Executives

Officer Age In this role 2025 pay Source
David Hallal Also a director
Chief Executive Officer and Chairman
59 Not stated $33,300,927
Vikas Sinha
Chief Financial Officer
62 Since 2025
1 year
$12,872,848
R. Keith Woods
Chief Operating Officer
58 Since 2025
1 year
$12,915,999
Akshay Vaishnaw M.D., Ph.D. Also a director
President of Research & Development
63 Since 2025
1 year
$14,891,367

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
9
serving now
Independent
4 of 4
stated in the proxy; 5 not stated
Average tenure
7.2 years
from year joined
CEO also chairs the board
Yes
David Hallal
Director Age On board Independent Committees Other public boards 2025 pay Source
David Hallal
59 2017
9 years
Not stated None stated ElevateBio, LLC, Kalaris Therapeutics, Inc. Paid as CEO
Akshay Vaishnaw, M.D., Ph.D.
63 2019
7 years
Not stated None stated Hemab Inc. Not stated
Kristina Burow
53 2014
12 years
Not stated
Compensation Committee · Chair
Neumora Therapeutics, Inc., Boundless Bio, Inc., Mirador Therapeutics, Inc., Treeline Biosciences, Inc., Magnet Biomedicine, Inc. $531,049
Michael Gilman
71 2013
13 years
Independent
Compensation Committee Science, Innovation and Technology Committee
None stated Not stated
Katie Peng
55 2024
2 years
Not stated
Audit Committee Compensation Committee
Adicet Bio, Inc. $531,138
Richard Brudnick
69 2023
3 years
Not stated
Audit Committee
InflaRx N.V. $524,524
Jeffrey S. Flier, M.D.
78 2016
10 years
Independent None stated None stated $540,662
Srinivas Akkaraju, M.D., Ph.D.
58 2022
4 years
Independent
Nominating and Corporate Governance Committee Science, Innovation and Technology Committee
Alumis, Inc., Mineralys Therapeutics Inc., vTv Therapeutics, Inc., Inventiva S.A., Kalaris Therapeutics, Inc. $526,027
Joshua Reed
53 2021
5 years
Independent
Nominating and Corporate Governance Committee
None stated $540,052

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

No related-party transactions disclosed

The proxy filed Apr 22, 2026 describes a review policy but reports no transactions.

Read the policy in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support